AUTHOR=Liu Rongrong , Ma Hongwei , Shu Jiayi , Zhang Qiang , Han Mingwei , Liu Ziyu , Jin Xia , Zhang Fanglin , Wu Xingan 

TITLE=Vaccines and Therapeutics Against Hantaviruses

JOURNAL=Frontiers in Microbiology

VOLUME=Volume 10 - 2019

YEAR=2020

URL=https://www.frontiersin.org/journals/microbiology/articles/10.3389/fmicb.2019.02989

DOI=10.3389/fmicb.2019.02989

ISSN=1664-302X

ABSTRACT=Hantaviruses (HVs) are rodent transmitted  viruses that can cause hemorrhagic fever with renal syndrome (HFRS) in Eurasia and hantavirus cardio-pulmonary syndrome (HCPS)in the Americas.  Together, these viruses cause   approximately 200,000humaninfections annually worldwide in recent years, with case fatality rate of 5-15%for HFRS and up to 40% for HCPS. There are currently no effective treatment available for either  HFRS or HCPS. The only vaccines licensed for use in Republic of Korea and China are based on  inactivated whole Seoul virus (SEOV) and Hantaan virus(HTNV), but the protective efficacy of these vaccines are uncertain.  To a large extent, the immune correlates of protection against Hantavirus are not known. In this review, we summarized the epidemiology, virology, and pathogenesis of four HFRS causing viruses, HTNV, SEOV, PUUV (Puumala virus), and DOBV (Dobrava-Belgrade virus); and two HCPS causing viruses, ANDV (Andes virus) and SNV (Sin Nombre virus); and then discussed the existing knowledge on vaccine and therapeutics against  these diseases.  We think these information will  shed lights on the rational development of new vaccines and treatment.